Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: Analysis of combined data from two phase III randomized clinical trials

Cancer

Volumn 104, Issue 4, 2005, Pages 864-868

  Gralla, Richard J ^a   De Wit, Ronald ^b   Herrstedt, Jorn ^c   Carides, Alexandra D ^d   Ianus, Juliana ^d   Guoguang Ma, Julie ^d   Evans, Judith K ^d   Morgan, Kevin J ^d  

^a New York Lung Cancer Alliance   (United States)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c Mental Health Services CPH   (Denmark)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiemetic; Aprepitant; Cancer; Nausea and vomiting; Neurokinin 1 antagonist; Supportive care

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; APREPITANT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PACLITAXEL; SEROTONIN 3 ANTAGONIST;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; POPULATION RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADRENAL CORTEX HORMONES; ANTHRACYCLINES; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; HUMANS; MALE; MORPHOLINES; NAUSEA; NEOPLASMS; ONDANSETRON; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; VOMITING;

EID: 23444449690     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21222     Document Type: Article

References (25)

1. Hesketh PJ. Treatment of chemotherapy-induced vomiting in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer. 1994;2:286-292.
2. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17:2971-2994.
3. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced vomiting: results of the Perugia Consensus Conference. Ann Oncol 1998;9:811-819.
4. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed vomiting. Drugs. 1996;52:639-648.
5. Kris MG. Why do we need another antiemetic? Jusk ask. J Clin Oncol. 2003;21:4077-4080.
6. Stieler JM. Treatment options for chemotherapy-induced nausea and vomiting. Am J Cancer. 2003;2:15-26.
7. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med. 1983;309:796.
8. Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer. 1985; 55:2766-2770.
9. Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin. 1989;39:89-104.
10. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997;15:116-123.
11. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced vomiting. Definition and validation of a predictive logistic model. Cancer. 1989;64:1117-1122.
12. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer. 2002;10:139-145.
13. Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from vomiting for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-15.
14. Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999;3:113-119.
15. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191-196.
16. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
17. Cubeddu LX. Serotonin mechanisms in chemotherapy-induced vomiting in cancer patients. Oncology. 1996;53(Suppl 1):18-25.
18. du Bois A, Vach W, Kiechle M, Cramer-Giraud U, Meerpohl H. Pathophysiology, severity, pattern, and risk factors for carboplatin-induced vomiting. Oncology. 1996;53(Suppl 1): 46-50.
19. Andrews PL, Naylor RJ, Joss RA. Neuropharmacology of vomiting and its relevance to anti-emetic therapy. Consensus and controversies. Support Care Cancer. 1998;6:197-203.
20. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced vomiting as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074-1080.
21. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol. 2003;21:4112-4119.
22. Poli-Bigelli S, Rodriguez-Pereira J, Guoguang-Ma J, et al. Addition of the NK1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer. 2003;97:3090-3098.
23. Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced vomiting. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer. 1992;66:192-197.
24. Martin M. The severity and pattern of vomiting following different cytotoxic agents. Oncology. 1996;53(Suppl 1):26-31.
25. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer. 1992;66:198-203.